Brain Activity in Adults With ADHD During Neuropsychological Tasks

April 6, 2022 updated by: Luca Remonda, Kantonsspital Aarau

Brain Activity and Functional Connectivity in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) During Tasks of Motor Inhibition and Cognitive Switching

The aim of the study is to investigate the response on cognitive testing of healthy persons compared to adults with or without medication against ADHD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most prevalent psychiatric disorders in children and adolescents. It is characterized by inattentive, hyperactive, impulsive behaviour and neuropsychological deficits. In 40-60% of cases emerge in childhood and persists into adulthood.

The aim of the study is to investigate the response on cognitive testing of healthy persons compared to adults with or without medication against ADHD. As a secondary endpoint a more robust diagnosing method combining advanced imaging methods with neuropsychological evaluation is tested.

Neuropsychological testing, functional MRI and spectroscopy will be performed. Statistical analysis will assess differences in the functional magnetic resonance imaging, spectroscopy and neuropsychological evaluation results between three groups: 1) group of healthy volunteers, 2) participants with ADHD with medication and 3) participants with ADHD without medication.

Study Type

Observational

Enrollment (Actual)

45

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • Aargau
      • Aarau, Aargau, Switzerland, 5001
        • Kantonsspital Aarau

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 51 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Three groups:

  1. healthy volunteers
  2. ADHD subjects receiving medications
  3. medication-naive ADHD subjects

Description

Inclusion Criteria:

  • Participant is between 20-55 years old
  • Participant is not pregnant

Exclusion Criteria:

  • Participant is not able to consent him/herself
  • Suspected or proven pregnancy
  • Nursing
  • Neurological diseases that could interfere with a diagnosis of ADHD
  • Psychiatric comorbidity under treatment
  • Previous history of psychiatric medication
  • Substance abuse
  • Intelligence quotient<75
  • Claustrophobia
  • Electrical simulator nerve or bone
  • Implanted medication infusion pump
  • Cerebral aneurysm clips
  • Unstable medical condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy volunteers
healthy volunteer between age of 20 to 55 will undergo MRI examination.
Device: MRI
Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
ADHD subjects without medication
Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
Device: MRI
Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
ADHD subjects with medication
Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
Device: MRI
Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in blood oxygenation level dependency (BOLD)
Time Frame: 2 hours
The study consist solely of one MRI examination performed within 2 hours.
2 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kantonsspital Aarau

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

May 1, 2020

Study Completion (Actual)

November 1, 2020

Study Registration Dates

First Submitted

August 3, 2015

First Submitted That Met QC Criteria

October 15, 2015

First Posted (Estimate)

October 16, 2015

Study Record Updates

Last Update Posted (Actual)

April 7, 2022

Last Update Submitted That Met QC Criteria

April 6, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1410.000.055

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Trials on MRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe